ProQR Therapeutics (PRQR) Competitors

$1.51 -0.08 (-5.03%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$1.54 +0.03 (+1.99%)

As of 03:59 AM Eastern

PRQR vs. CTMX, CYRX, ZVRA, CLYM, and CADL

Should you buy ProQR Therapeutics stock or one of its competitors? MarketBeat compares ProQR Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ProQR Therapeutics include CytomX Therapeutics (CTMX), CryoPort (CYRX), Zevra Therapeutics (ZVRA), Climb Bio (CLYM), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry.

How does ProQR Therapeutics compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

CytomX Therapeutics has a net margin of -166.40% compared to ProQR Therapeutics' net margin of -331.33%. CytomX Therapeutics' return on equity of -36.61% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

CytomX Therapeutics has higher revenue and earnings than ProQR Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.82	-$17.37M	-$0.41	N/A
ProQR Therapeutics	$17.99M	8.84	-$47.73M	-$0.50	N/A

CytomX Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

CytomX Therapeutics currently has a consensus target price of $12.78, suggesting a potential upside of 265.08%. ProQR Therapeutics has a consensus target price of $7.25, suggesting a potential upside of 380.13%. Given ProQR Therapeutics' higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, CytomX Therapeutics had 7 more articles in the media than ProQR Therapeutics. MarketBeat recorded 11 mentions for CytomX Therapeutics and 4 mentions for ProQR Therapeutics. CytomX Therapeutics' average media sentiment score of 0.93 beat ProQR Therapeutics' score of 0.30 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProQR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 6.6% of CytomX Therapeutics shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

CytomX Therapeutics beats ProQR Therapeutics on 12 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to CryoPort?

CryoPort (NASDAQ:CYRX) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

CryoPort has a net margin of 41.57% compared to ProQR Therapeutics' net margin of -331.33%. CryoPort's return on equity of -7.92% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

CryoPort presently has a consensus price target of $14.44, suggesting a potential upside of 8.47%. ProQR Therapeutics has a consensus price target of $7.25, suggesting a potential upside of 380.13%. Given ProQR Therapeutics' higher possible upside, analysts plainly believe ProQR Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

CryoPort has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

In the previous week, ProQR Therapeutics had 3 more articles in the media than CryoPort. MarketBeat recorded 4 mentions for ProQR Therapeutics and 1 mentions for CryoPort. CryoPort's average media sentiment score of 0.56 beat ProQR Therapeutics' score of 0.30 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProQR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 10.1% of CryoPort shares are owned by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CryoPort has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	3.81	$78.30M	$1.35	9.86
ProQR Therapeutics	$17.99M	8.84	-$47.73M	-$0.50	N/A

Summary

CryoPort beats ProQR Therapeutics on 13 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Zevra Therapeutics has a net margin of 101.58% compared to ProQR Therapeutics' net margin of -331.33%. Zevra Therapeutics' return on equity of 51.49% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

Zevra Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market.

In the previous week, ProQR Therapeutics had 3 more articles in the media than Zevra Therapeutics. MarketBeat recorded 4 mentions for ProQR Therapeutics and 1 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.62 beat ProQR Therapeutics' score of 0.30 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ProQR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zevra Therapeutics has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	5.79	$83.23M	$1.99	5.24
ProQR Therapeutics	$17.99M	8.84	-$47.73M	-$0.50	N/A

Zevra Therapeutics presently has a consensus target price of $23.33, suggesting a potential upside of 123.71%. ProQR Therapeutics has a consensus target price of $7.25, suggesting a potential upside of 380.13%. Given ProQR Therapeutics' higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Zevra Therapeutics beats ProQR Therapeutics on 12 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to Climb Bio?

ProQR Therapeutics (NASDAQ:PRQR) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Climb Bio had 12 more articles in the media than ProQR Therapeutics. MarketBeat recorded 16 mentions for Climb Bio and 4 mentions for ProQR Therapeutics. Climb Bio's average media sentiment score of 0.69 beat ProQR Therapeutics' score of 0.30 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by insiders. Comparatively, 2.6% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ProQR Therapeutics has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market.

ProQR Therapeutics has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	8.84	-$47.73M	-$0.50	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

ProQR Therapeutics currently has a consensus price target of $7.25, suggesting a potential upside of 380.13%. Climb Bio has a consensus price target of $20.30, suggesting a potential upside of 105.47%. Given ProQR Therapeutics' higher probable upside, equities research analysts plainly believe ProQR Therapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08

Climb Bio has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Climb Bio's return on equity of -31.45% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Climb Bio	N/A	-31.45%	-30.39%

Summary

Climb Bio beats ProQR Therapeutics on 9 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to Candel Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Candel Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Candel Therapeutics' return on equity of -60.42% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Candel Therapeutics	N/A	-60.42%	-41.33%

ProQR Therapeutics has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.59, indicating that its share price is 159% less volatile than the broader market.

In the previous week, Candel Therapeutics had 15 more articles in the media than ProQR Therapeutics. MarketBeat recorded 19 mentions for Candel Therapeutics and 4 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 0.30 beat Candel Therapeutics' score of 0.06 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Candel Therapeutics has lower revenue, but higher earnings than ProQR Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	8.84	-$47.73M	-$0.50	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

ProQR Therapeutics presently has a consensus target price of $7.25, suggesting a potential upside of 380.13%. Candel Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 127.85%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe ProQR Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

ProQR Therapeutics beats Candel Therapeutics on 9 of the 14 factors compared between the two stocks.

Get ProQR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRQR vs. The Competition

Export

Metric	ProQR Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$167.52M	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.80%	5.32%
P/E Ratio	-3.02	18.13	20.64	25.23
Price / Sales	8.84	289.87	554.85	79.36
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	2.85	6.57	9.66	6.63
Net Income	-$47.73M	$24.35M	$3.56B	$335.59M
7 Day Performance	-5.63%	-2.53%	-1.65%	-1.20%
1 Month Performance	-24.12%	-3.55%	-2.60%	-1.16%
1 Year Performance	-11.70%	53.51%	30.07%	28.10%

ProQR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRQR ProQR Therapeutics	3.4242 of 5 stars	$1.51 -5.0%	$7.25 +380.1%	-6.8%	$167.52M	$17.99M	N/A	180	Earnings Report Analyst Downgrade
CTMX CytomX Therapeutics	3.2091 of 5 stars	$3.88 +0.5%	$12.78 +229.3%	+72.4%	$660.34M	$76.20M	N/A	170
CYRX CryoPort	3.2409 of 5 stars	$13.04 -1.0%	$14.44 +10.7%	+99.3%	$657.22M	$176.18M	9.66	1,186
ZVRA Zevra Therapeutics	3.9198 of 5 stars	$11.05 +2.3%	$23.33 +111.2%	+20.4%	$653.28M	$106.47M	5.55	20
CLYM Climb Bio	3.278 of 5 stars	$11.17 +0.4%	$20.30 +81.7%	+665.9%	$639.59M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRQR) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProQR Therapeutics (PRQR) Competitors

PRQR vs. CTMX, CYRX, ZVRA, CLYM, and CADL

How does ProQR Therapeutics compare to CytomX Therapeutics?

Summary

How does ProQR Therapeutics compare to CryoPort?

Summary

How does ProQR Therapeutics compare to Zevra Therapeutics?

Summary

How does ProQR Therapeutics compare to Climb Bio?

Summary

How does ProQR Therapeutics compare to Candel Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProQR Therapeutics (PRQR) Competitors

PRQR vs. CTMX, CYRX, ZVRA, CLYM, and CADL

How does ProQR Therapeutics compare to CytomX Therapeutics?

Is CTMX or PRQR more profitable?

Which has higher earnings and valuation, CTMX or PRQR?

Which has more risk & volatility, CTMX or PRQR?

Do analysts prefer CTMX or PRQR?

Does the media refer more to CTMX or PRQR?

Do institutionals & insiders hold more shares of CTMX or PRQR?

Summary

How does ProQR Therapeutics compare to CryoPort?

Is CYRX or PRQR more profitable?

Do analysts prefer CYRX or PRQR?

Which has more volatility & risk, CYRX or PRQR?

Does the media prefer CYRX or PRQR?

Do insiders & institutionals hold more shares of CYRX or PRQR?

Which has preferable valuation and earnings, CYRX or PRQR?

Summary

How does ProQR Therapeutics compare to Zevra Therapeutics?

Is ZVRA or PRQR more profitable?

Which has more risk and volatility, ZVRA or PRQR?

Does the media refer more to ZVRA or PRQR?

Which has stronger earnings and valuation, ZVRA or PRQR?

Do analysts prefer ZVRA or PRQR?

Do institutionals and insiders have more ownership in ZVRA or PRQR?

Summary

How does ProQR Therapeutics compare to Climb Bio?

Does the media favor PRQR or CLYM?

Do insiders and institutionals hold more shares of PRQR or CLYM?

Which has more volatility & risk, PRQR or CLYM?

Which has stronger earnings and valuation, PRQR or CLYM?

Do analysts recommend PRQR or CLYM?

Is PRQR or CLYM more profitable?

Summary

How does ProQR Therapeutics compare to Candel Therapeutics?

Do insiders & institutionals hold more shares of PRQR or CADL?

Is PRQR or CADL more profitable?

Which has more risk and volatility, PRQR or CADL?

Does the media refer more to PRQR or CADL?

Which has better earnings & valuation, PRQR or CADL?

Do analysts recommend PRQR or CADL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools